Assessment of salivary cotinine concentration among general non-smokers population: Before and after Spanish smoking legislations |
| |
| Affiliation: | 1. Group of Evaluation of Health Determinants and Health Policies, Department of Basic Sciences, Universitat Internacional de Catalunya, Sant Cugat del Vallès, Spain;2. Tobacco Control Unit, Cancer Prevention and Control Program, Institut Català d’Oncologia, L''Hospitalet de Llobregat, Barcelona, Spain;3. Cancer Prevention and Control Group, Institut d''Investigació Biomèdica de Bellvitge – IDIBELL, L''Hospitalet de Llobregat, Barcelona, Spain;4. Department of Clinical Sciences, School of Medicine, Universitat de Barcelona, Barcelona, Spain;5. Group of Integrative Pharmacology and Systems Neuroscience, Neurosciences Programme, IMIM (Hospital del Mar Medical Research Institute), Parc de Recerca Biomèdica de Barcelona, Barcelona, Spain;6. Catalan Network of Smoke-free Hospitals, L’Hospitalet de Llobregat, Barcelona, Spain;7. Addictions Unit, Institute of Neurosciences, Hospital Clínic de Barcelona, Barcelona, Spain;8. Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Parc de Recerca Biomèdica de Barcelona, Barcelona, Spain;1. Collaboration for Cancer Outcomes, Research and Evaluation, The Ingham Institute for Applied Medical Research, Liverpool Hospital, UNSW, Sydney, Australia;2. Applied Radiation Biology and Radiotherapy Section, Division of Human Health e Department of Nuclear Sciences and Applications, International Atomic Energy Agency, PO Box 100, 1400 Vienna, Austria;1. Department of Pediatrics, Chung-Ang University Hospital, Seoul, Republic of Korea;2. Department of Internal Medicine, Nasaret International Hospital, Incheon, Republic of Korea;3. Department of Clinical Epidemiology and Biostatistics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea;4. College of Medicine, Chung-Ang University, Seoul, Republic of Korea;5. Department of Pediatrics, Asan Medical Center, Children’s Hospital, University of Ulsan College of Medicine, Seoul, Republic of Korea;1. Department of Family Medicine and Community Health, JABSOM – University of Hawaii at Manoa, 677 Ala Moana Blvd, Suite 815, Honolulu, HI 96813, United States;2. Yap State Department of Health Services, P.O. Box 1010, Colonia, Yap 96943, Federated States of Micronesia;1. Service de Gynécologie-Obstétrique Centre Hospitalier Universitaire de Guadeloupe, Guadeloupe F.W.I. Route de Chauvel, 97159 Pointe-à-Pitre Cedex, France;2. Institut National de la Santé et de la Recherche Médicale Inserm U1085–IRSET, Campus Universitaire de Fouillole, Pointe à Pitre 97157, Guadeloupe, France;3. Service d’Anatomopathologie, Centre Hospitalier Universitaire de Guadeloupe, Guadeloupe F.W. I. Route de Chauvel, 97159 Pointe-à-Pitre Cedex, France;4. Registre Général des Cancers de Guadeloupe, Centre Hospitalier Universitaire de Guadeloupe, Guadeloupe F.W. I. Route de Chauvel, 97159 Pointe-à-Pitre Cedex, France;1. Registre des cancers du Bas-Rhin, U1113, FMTS, Université de Strasbourg, 4 rue Kirschleger, 67085 Strasbourg, France;2. Service de santé publique, Hôpitaux Universitaires de Strasbourg, 1 place de l’hôpital, 67091 Strasbourg, France;3. Registre des cancers de la Manche, Centre Hospitalier Public du Cotentin, 46 rue du Val de Saire, 50102 Cherbourg-Octeville, France;4. Registre des tumeurs de l''Hérault, Centre de Recherche, 208 rue des Apothicaires, 34298 Montpellier, France;5. Registre général des tumeurs du Calvados, Cancers & Préventions – U1086 Inserm, Centre François Baclesse, Avenue du Général Harris BP 5026, 14076 Caen, France;6. Registre des tumeurs du Doubs et du Territoire de Belfort, EA3181, Centre Hospitalier Régional Universitaire, 25030 Besançon, France;7. Registre des cancers du Tarn, 1, rue Lavazière, BP 37, 81001 Albi cedex, France;8. Institut Claudius Regaud, Centre régional de lutte contre le cancer, IUCT-O, Registre des cancers du Tarn, 31059 Toulouse, France;9. Registre des hémopathies malignes de Basse-Normandie, Unité Fonctionnelle Hospitalo-Universitaire n°0350, Centre Hospitalier Universitaire, Avenue de la Côte de Nacre, 14033 Caen, France;10. Registre des cancers de l’Isère, CHU de Grenoble, Pavillon E BP 217, 38043 Grenoble 9, France;11. Registre du cancer de la Somme, Service Épidémiologie Hygiène et Santé Publique, CHU Nord, 80054 Amiens, France;12. Service d’épidémiologie et de biostatistique, Centre Paul Strauss, 3 rue de la Porte de l’hôpital, 67065 Strasbourg, France;1. Department of Oncology, Queen’s University, Kingston, Canada;2. Department of Surgery, Queen’s University, Kingston, Canada;3. Division of Cancer Care and Epidemiology, Queen’s University Cancer Research Institute, Canada |
| |
| Abstract: | BackgroundIn Spain, two smoke-free laws have been passed (Law 28/2005 and Law 42/2010).This study evaluates the association between Spanish smoking legislations and the second-hand smoke (SHS) exposure in an adult non-smoking population cohort in Barcelona (Spain).MethodsThis is a longitudinal study, before and after the implementation of two national smoking bans, in a representative sample of adults (≥16 years old) from Barcelona (Spain) surveyed in 2004–2005 and followed up in 2013–2014 (n = 736). We only analyzed non-smokers (n = 397). We obtained 9 ml of saliva sample for analysis of cotinine, a biomarker of recent tobacco exposure. We calculated geometric means of salivary cotinine concentration and their geometric standard deviation. We used linear mixed effect models, with individuals as random effects, to model the percentage change in salivary cotinine concentration and their 95% confidence intervals.ResultsThe percentage of participants with saliva samples with measurable concentrations of cotinine fell from 92.4% to 64.2% after both Spanish smoking legislations. The geometric mean of salivary cotinine concentration significantly decreased 88% (from 0.98 ng/mL to 0.12 ng/mL, p < 0.001) after the implementation of the two Spanish smoke-free legislations. The decrease of the GM salivary cotinine concentration was statistically significant independently of the sociodemographic variables.ConclusionThere was a large reduction in the salivary cotinine concentration among adult non-smokers and higher cotinine concentrations among those declaring exposure to SHS at home after both legislations. Moreover, after both Spanish smoke-free laws salivary cotinine concentration was homogenized according to sociodemographic variables. |
| |
| Keywords: | Smoke-free legislation Cotinine Biomarker |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
